Completed durable response of advanced endometrial cancer treated with pembrolizumab without surgical intervention or systemic chemotherapy: A case report

Completed durable response of advanced endometrial cancer treated with pembrolizumab without surgical intervention or systemic chemotherapy: A case report

Endometrial cancer remains the most common gynecologic malignancy in the United States. Novel molecular targets are being explored for treatment of advanced uterine. Molecular targets in signaling cascades have been identified including immune checkpoint inhibitors. This is a case of 63-year-old G0...

Full description

Bibliographic Details
Main Authors:	Anusha Adkoli, Rodrigo Alcorta Proaño, Eugenia Girda
Format:	Article
Language:	English
Published:	Elsevier 2024-06-01
Series:	Current Problems in Cancer: Case Reports
Subjects:	Case report Endometrial cancer Pembrolizumab Genetics Molecular testing
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666621924000085

Similar Items

Durable complete remission after Pembrolizumab in pretreated advanced endometrial cancer: A case report
by: Nicoletta Provinciali, et al.
Published: (2022-09-01)

Lenvatinib and pembrolizumab versus platinum doublet chemotherapy as second-line therapy for advanced or recurrent endometrial cancer
by: Yutaka Yoneoka, et al.
Published: (2024-11-01)

Long-term disease-free survival with chemotherapy and pembrolizumab in a patient with unmeasurable, advanced stage dedifferentiated endometrial carcinoma
by: Joy M. Davis, et al.
Published: (2024-06-01)

Activity of pembrolizumab and lenvatinib in mismatch repair deficient (dMMR) endometrial cancer patients who have failed pembrolizumab monotherapy: A case series
by: Peter G. Rose, et al.
Published: (2023-12-01)

Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab
by: Nicoletta Colombo, et al.
Published: (2023-12-01)

Lenvatinib Plus Pembrolizumab vs. Chemotherapy in Pretreated Patients With Advanced Endometrial Cancer: A Cost-Effectiveness Analysis
by: Mingyang Feng, et al.
Published: (2022-05-01)

Exceptional Response to Pembrolizumab for Treatment of Metastatic Chemorefractory Endometrial Carcinoma in a Patient with Lynch Syndrome: A Case Report
by: Samantha Batman, et al.
Published: (2023-04-01)

Sustained response to lenvatinib and pembrolizumab in two patients with KRAS-mutated endometrial mesonephric-like adenocarcinoma
by: Sherry Shen, et al.
Published: (2021-08-01)

Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma
by: Domenica Lorusso, et al.
Published: (2022-09-01)

Efficacy and safety of pembrolizumab in patients with advanced endometrial cancer: a systematic review and meta-analysis
by: Biqiong Pan, et al.
Published: (2025-02-01)

Efficacy and safety of lenvatinib plus pembrolizumab in patients with advanced and recurrent endometrial cancer: a systematic review and meta-analysis
by: Guangwei Yan, et al.
Published: (2024-08-01)

Corrigendum: Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma
by: Domenica Lorusso, et al.
Published: (2023-08-01)

Possible applications for combined lenvatinib and pembrolizumab in advanced endometrial carcinoma
by: K. V. Menshikov, et al.
Published: (2023-01-01)

Cost-effectiveness analysis of lenvatinib plus pembrolizumab compared with chemotherapy for patients with previously treated mismatch repair proficient advanced endometrial cancer in China
by: Zhiwei Zheng, et al.
Published: (2022-09-01)

Efficacy and safety of lenvatinib and pembrolizumab in the treatment of endometrial cancer: data from routine clinical practice in Russia
by: A. A. Rumyantsev, et al.
Published: (2024-01-01)

Case report: Durable response after pembrolizumab in combination with radiation - induced abscopal effect in platinum - refractory metastatic endometrial clear cell carcinoma
by: Chien-Hsiang Kao, et al.
Published: (2022-12-01)

The long-term clinical efficacy and safety of lenvatinib plus pembrolizumab in endometrial cancer: data from routine clinical practice in Russia
by: A. E. Protasova, et al.
Published: (2024-11-01)

Long term treatment of advanced endometrial cancer with lenvatinib and pembrolizumab
by: Sahana Somasegar, et al.
Published: (2025-04-01)

Pembrolizumab plus lenvatinib in advanced endometrial cancer: case report and systematic review of lung toxicity
by: Nicoletta Staropoli, et al.
Published: (2023-07-01)

The efficacy and safety of lenvatinib plus pembrolizumab therapy in patients with uterine carcinosarcoma
by: Risako Ozawa, et al.
Published: (2024-10-01)

Rhabdomyolysis following single administration of pembrolizumab: Is severe immune-reaction a marker for durable treatment response?
by: Varun Khetan, et al.
Published: (2021-02-01)

Lenvatinib and pembrolizumab in the treatment of metastatic endometrial cancer: literature review and case report
by: A. A. Rumyantsev
Published: (2021-12-01)

Lenvatinib and pembrolizumab in patients with advanced uterine cancer
by: A. G. Kedrova, et al.
Published: (2021-01-01)

Secondary Adrenal Insufficiency Due to Isolated ACTH Deficiency Induced by Pembrolizumab: A Report of Two Cases of Uterine Endometrial Cancer
by: Ichiro Onoyama, et al.
Published: (2023-04-01)

Case report: Posterior reversible encephalopathy syndrome, an adverse effect of lenvatinib and pembrolizumab combination therapy, in a patient with advanced endometrial cancer
by: Yuki Matsuura, et al.
Published: (2023-01-01)

A complete durable response of vaginal clear cell carcinoma with pembrolizumab: A case report
by: Hector S. Porragas-Paseiro, et al.
Published: (2023-10-01)

A case of relapsing aseptic meningitis under excellent tumor response to pembrolizumab in microsatellite instability-high recurrent endometrial cancer
by: Daito Noguchi, et al.
Published: (2021-11-01)

A case of complete remission of intractable gestational choriocarcinoma with subsequent chemotherapy after pembrolizumab
by: Kaoru Niimi, et al.
Published: (2023-09-01)

Durable Clinical Benefit after Dual Checkpoint Inhibition and Single-agent Nivolumab Following Pembrolizumab Failure in Mismatch Repair-deficient Colon Cancer
by: Yat-Fung Chow, et al.
Published: (2023-10-01)

Recurrent high grade serous endometrial cancer with brain metastases: Immunotherapy confers improved quality of life and survival
by: Kierany B. Shelvin, et al.
Published: (2024-10-01)

Complete and durable response of pulmonary large‐cell neuroendocrine carcinoma to pembrolizumab
by: Naoki Kadota, et al.
Published: (2022-08-01)

Tumor lenvatinib addiction and withdrawal rebound response in patients with advanced endometrial cancer
by: Clarissa Lam, et al.
Published: (2023-10-01)

Rapid regression of microsatellite instability-high/programmed cell death ligand 1-negative recurrent endometrial carcinoma by immune checkpoint blockade with pembrolizumab: A case report and literature review
by: Akihiro Takeda, et al.
Published: (2020-05-01)

Efficient sequence of therapy for advanced and metastatic endometrial cancer
by: A. A. Rumyantsev
Published: (2022-09-01)

Clinical and morphological features in patients with advanced endometrial cancer treated with immunotargeting therapy
by: L. A. Kolomiets, et al.
Published: (2023-08-01)

Development of drug-induced arthritis in a glioblastoma patient treated with pembrolizumab
by: Casey B Brown, et al.
Published: (2018-01-01)

Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC
by: Ya Chen, et al.
Published: (2021-04-01)

Combination pembrolizumab and lenvatinib in metastatic mismatch repair deficient adenocarcinoma of Mullerian origin: A case report
by: Jessica M. Velasquez, et al.
Published: (2024-06-01)

De-Escalated Adjuvant Treatment for Advanced MMR Deficient Mixed Endometrioid/Clear Cell Endometrial Carcinoma with PD-1 Inhibition Alone: A Case Report
by: Danielle M. Blemur, et al.
Published: (2024-08-01)

Durable response to pembrolizumab in microsatellite instability‐high advanced adrenocortical carcinoma
by: Masaya Senda, et al.
Published: (2023-11-01)